#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepatic angiosarcoma Anti-myelin-associated glycoprotein antibodies positive Lymphatic malformation Atypical haemolytic uraemic syndrome Eosinophilic granulomatosis with polyangiitis Short-bowel syndrome Angiosarcoma recurrent Squamous cell carcinoma of the cervix Ehlers-Danlos syndrome Infertility female Arrhythmia B-cell lymphoma Hereditary haemorrhagic telangiectasia Haemophilia A with anti factor VIII Myelofibrosis More trials…

    Learn about Rare Diseases

    Factor VIII deficiency Bronchiolitis obliterans syndrome – Trials in Disease Carcinoid syndrome – Treatment Methylmalonic acidaemia – Treatment Haemophilia B without inhibitors – Treatment Behcet’s syndrome Richter’s syndrome – Diagnostics Advanced systemic mastocytosis – Life with Disease Haemolytic uraemic syndrome – Treatment Pituitary-dependent Cushing’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Imiglucerase Prasugrel Tislelizumab Octreotide Acetate Abacavir Chlorphenamine Aminohippuric Acid Damoctocog Alfa Pegol Warfarin Ursodeoxycholic Acid Glyceryl Trinitrate Tiaprofenic Acid Abc-35B-116 Human Coagulation Factor Ix FG001 Thiotepa Bleomycin Sulfate Ph. Eur. Olaptesed Pegol Folic Acid [18F]CPFPX More therapies…

    Learn about Your Condition

    Normal pressure hydrocephalus Hereditary optic atrophy Dyslipidaemia Hip arthroplasty Prostate cancer metastatic Endometrial cancer stage IV Ligament operation Dry eye Salivary gland cancer Deep vein thrombosis Toxicity to various agents Pneumothorax Urinary incontinence Oxygen saturation Lung adenocarcinoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    Belgium Bulgaria Czechia France Germany Greece +5

  • Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Divarasib
    • Nivolumab
    • Pembrolizumab
    Austria Belgium France Germany Greece Italy +2

  • Phase 2 Neoadjuvant Study of Amivantamab with Lazertinib in Resectable EGFR‑Mutated Non‑Small Cell Lung Cancer Patients

    Recruiting

    2 1 1
    Investigated Drugs:
    • Amivantamab
    • Lazertinib
    Spain

  • Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Pembrolizumab
    Austria Bulgaria France Germany Greece Italy +4

  • Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Rmc-6291
    • (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    Belgium France Germany Greece Ireland Italy +3

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Durvalumab
    France Germany Greece Italy The Netherlands Poland +1
1 2 3 … 55
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!